CJC-1295 + Ipamorelin Blend
Research Use Only
This product is intended for laboratory research purposes only. It is not intended for human or veterinary use, food, cosmetic, household, or agricultural applications. Not for human consumption.
Overview
The CJC-1295 + Ipamorelin Blend combines a GHRH analog (CJC-1295 no DAC) with a selective GHRP (Ipamorelin) in a single, pre-formulated research compound. This combination is designed for studying the synergistic effects of simultaneous GHRH and GHRP pathway activation, which research has shown produces significantly greater GH release than either peptide alone.
Blend Composition
| Component | Amount | Pathway |
|---|---|---|
| CJC-1295 (no DAC) | 2.5mg or 5mg | GHRH Receptor |
| Ipamorelin | 2.5mg or 5mg | Ghrelin Receptor (GHS-R1a) |
Synergistic Mechanisms
The combination creates multi-pathway GH stimulation:
Complementary Receptor Activation
CJC-1295 (GHRH Pathway):
- Stimulates GH synthesis
- Increases GH pulse amplitude
- cAMP-mediated signaling
- Somatotroph priming
Ipamorelin (GHRP Pathway):
- Triggers GH release
- Increases GH pulse frequency
- Ghrelin receptor activation
- Minimal side effects
Synergistic Effects
- Amplified GH Release - Combined effect exceeds additive sum
- Optimized Pulse Pattern - Both amplitude and frequency enhanced
- Selectivity Maintained - Ipamorelin's clean profile preserved
- Feedback Preservation - Natural regulation maintained
Research Applications
Synergy Quantification Studies
- Comparative efficacy vs. single peptides
- Dose-response relationships
- Timing optimization research
- Mechanism interaction studies
GH Pathway Research
- Dual receptor activation dynamics
- Signal integration studies
- Downstream IGF-1 effects
- Feedback mechanism research
Protocol Development
- Administration timing studies
- Frequency optimization
- Long-term protocol research
- Safety profile assessment
Available Formats
| Size | Composition | Catalog Code |
|---|---|---|
| 5mg Total | 2.5mg CJC + 2.5mg Ipa | CJCIPA-5 |
| 10mg Total | 5mg CJC + 5mg Ipa | CJCIPA-10 |
Handling & Storage
- Store lyophilized blend at -20°C
- Protect from light and moisture
- Reconstitute with bacteriostatic water
- Reconstituted solution stable at 2-8°C for up to 3 weeks
- Blend is pre-mixed; do not attempt to separate
- Use sterile technique during handling
Quality Specifications
- Individual Component Purity: ≥99% by HPLC
- Blend Homogeneity: Verified
- Appearance: White lyophilized powder
- Solubility: Soluble in water
- Endotoxin: Less than 1 EU/mg
- Certificate of Analysis for each component
Advantages of Pre-Blending
- Precise Ratios - Consistent 1:1 ratio in every vial
- Convenience - Single reconstitution
- Reduced Error - No mixing calculations
- Stability Tested - Verified compatibility
Research Context
Studies have demonstrated that combined GHRH and GHRP administration produces:
- 3-5x greater GH release than either alone
- More consistent response patterns
- Maintained pulsatile secretion profile
- No tachyphylaxis with appropriate protocols
References
- Bowers CY. "GH releasing peptides—structure and kinetics." J Pediatr Endocrinol. 1993.
- Veldhuis JD, et al. "Dual defects in pulsatile growth hormone secretion and clearance." J Clin Endocrinol Metab. 2002.
- Ionescu M, et al. "Pulsatile secretion of growth hormone persists during continuous stimulation." Endocrinology. 2004.